The International Journal of Romanian Society of Endocrinology / Registered in 1938

in ISI Thomson Master Journal List

Acta Endocrinologica(Bucharest) is live in PubMed Central

January - March 2020, Volume 16, Issue 1
Case Report

Kulshreshtha B, Chopra A, Aggarwal A, Baxi K

Thyroiditis Developing Post Initiation of Octreotide in a Case of TSH Secreting Tumor

Acta Endo (Buc) 2020, 16 (1): 90-94
doi: 10.4183/aeb.2020.90

Thyroiditis developing post pituitary surgery in a case of TSH secreting tumor has been reported, albeit rarely. A 46 year old female was treated as a case of hypothyroidism for almost five years, however, TSH levels remained unsuppressed in spite of increasing thyroxine doses. A cyclic pattern of TSH with T3 secretion was observed after stopping thyroxine, though T4 levels were normal. T3 suppression test revealed a non suppressed TSH and MRI sella revealed a pituitary mass with Grade 1 cavernous sinus invasion. With a diagnosis of TSH secreting tumor, the patient was initiated on octreotide therapy. TFT normalized within 4 days of initiation of octreotide, tumor size reduced by about 30% within 2 months of therapy and goiter size reduced to almost half with octreotide therapy. Anti TPO levels which were initially negative became positive within a month of octreotide therapy and FNAC thyroid revealed thyroiditis. To the best of our knowledge, this is the second case report of development of thyroiditis after octreotide therapy. The immunomodulatory role of TSH and somatostatin may have a role in the development of thyroiditis in this case.

Keywords: TSH Secreting Tumor, Somatostatin, Thyroiditis.

Correspondence: Bindu Kulshreshtha MD, “Dr Ram Manohar Lohia” Hospital, Post Graduate Institute of Medical Education & Research, Dept. of Endocrinology, New Delhi, 110001, India, E-mail: